(ORGO) News: Did You Suffer a Substantial Loss? Contact Johnson Fistel About Organogenesis Holdings Inc. Class Action Lawsuit

San Diego, California--(Newsfile Corp. - January 29, 2022) - Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Organogenesis Holdings Inc. (NASDAQ: ORGO) who purchased between March 17, 2021 and October 11, 2021. To serve as lead plaintiff in this class action, you must move the Court no later than February 8, 2022.

What actions may I take at this time? If you suffered a substantial loss and are interested in learning more about being a lead plaintiff, please contact Jim Baker (jimb@johnsonfistel.com) by email or phone at 619-814-4471. If emailing, please include a phone number. Additionally, you can:

To join this action, you can go to: https://www.cognitoforms.com/JohnsonFistel/organogenesisholdingsinc or [Click here to join this action]. There is no cost or obligation to you.

Organogenesis is a regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets in the United States. Organogenesis' products include, among others, "Affinity" and "PuraPly XT."

The Organogenesis class action lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) Organogenesis improperly billed the federal government for its Affinity and PuraPly XT products by, among other things, setting the price for those products multiple times higher than similar products; (ii) Organogenesis improperly induced doctors to use its Affinity and PuraPly XT products through lucrative reimbursements; (iii) as a result, Organogenesis' revenue and profits derived from its Affinity and PuraPly XT products were at least in substantial part unsustainable; and (iv) thus, Organogenesis' public statements were materially false and misleading at all relevant times.

A lead plaintiff will act on behalf of all other class members in directing the Organogenesis class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the Organogenesis class action lawsuit is not dependent upon serving as lead plaintiff.

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
jimb@johnsonfistel.com

To join this action, you can go to: https://www.cognitoforms.com/JohnsonFistel/organogenesisholdingsinc or [Click here to join this action]. There is no cost or obligation to you.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112062